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Abstract
The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare
systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers. Whereas some
of the established oral hypoglycaemic drug classes like biguanide, sulphonylureas, thiazolidinediones have been extensively
used, the newer agents like dipeptidyl peptidase-4 (DPP-4) inhibitors and the human glucagon-like peptide-1 (GLP-1)
analogues have recently emerged as suitable options due to their similar efficacy and favorable side effect profiles. These
agents are widely recognized alternatives to the traditional oral hypoglycaemic agents or insulin, especially in conditions
where they are contraindicated or unacceptable to patients. Many studies which evaluated their clinical effects, either alone
or as add-on agents, were conducted in Western countries. There exist few reviews on their effectiveness in the Asia-Pacific
region. The purpose of this systematic review is to address the comparative effectiveness of these new classes of
medications as add-on therapies to sulphonylurea drugs among diabetic patients in the Asia-Pacific countries. We
conducted a thorough literature search of the MEDLINE and EMBASE from the inception of these databases to August 2013,
supplemented by an additional manual search using reference lists from research studies, meta-analyses and review articles
as retrieved by the electronic databases. A total of nine randomized controlled trials were identified and described in this
article. It was found that DPP-4 inhibitors and GLP-1 analogues were in general effective as add-on therapies to existing
sulphonylurea therapies, achieving HbA1c reductions by a magnitude of 0.59–0.90% and 0.77–1.62%, respectively. Few
adverse events including hypoglycaemic attacks were reported. Therefore, these two new drug classes represent novel
therapies with great potential to be major therapeutic options. Future larger-scale research should be conducted among
other Asia-Pacific region to evaluate their efficacy in other ethnic groups.
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Introduction
Epidemiology & burden of diabetes mellitus
Diabetes mellitus is the most common non-communicable
disease and a worldwide health crisis [1]. The previously reported
prevalence of diabetes was estimated as 9.3% from the National
Health and Nutrition Examination Survey (NHANES) in the
United States [2]. Similar high rates were also reported in
European countries such as Spain (10.3%) [3] and Poland (15%)
[4]. In Asia-Pacific region, a previous study described a
progressively rising trend of diabetes across the years from 2001
to 2008 in Hong Kong and the prevalence of diabetes escalated
with age [5]. Another study reported that the prevalence of
diabetes has reached epidemic proportions in the general
population aged 20 years and older in mainland China, where
9.7% of the adult population suffered from diabetes [6]. A recent
report from the International Diabetes Federation further revealed
that the estimated global prevalence of diabetic patients was
projected to increase from 2.8% in 2000–2007 to 9.9% in 2025–
2030, affecting a total of 552 million population [7]. Such
epidemiological evidence indicates that significant surge in the
incidence of diabetes is expected in the next few decades. There
has also been sound evidence suggesting that the rapidly escalating
prevalence of diabetes has imposed a substantial economic burden
at the society level, including the healthcare systems [8]. In 2011,
the estimated global health care expenditure due to diabetes was
US$465 million, accounting for approximately 11% of total health
expenditure among adults in the world [9]. In addition, diabetes is
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associated with excess morbidity and mortality [10,11] which
could lead to reduction of health-related quality of life and life
expectancy [12]. Its associated comorbidities increase hospitalisa-
tion rates due to the risk of long-term complications, such as
coronary artery disease, stroke, diabetic neuropathy, renal failure,
blindness, and peripheral vascular disease which might require
limb amputation [13,14]. Type 2 diabetes accounts for around
90% of diabetes cases and it is the most common form that is
associated with ageing population, environmental changes, and
health behaviour patterns. The optimal control of type 2 diabetes
has therefore significantly emerged as one of the most challenging
issues faced by physicians and policy-makers worldwide.
Traditional drugs used for diabetes mellitus
Metformin has been used alone as the first line OHA for type 2
diabetes [15–18]. It reduces hepatic glucose output and promotes
peripheral glucose uptake [19]. Its ability to reduce glycated
haemoglobin (HbA1c) is dose-related [20]. However, adverse
events (AEs) such as gastrointestinal disturbance and lactic acidosis
were reported [17]. Sulphonylureas (SUs) and thiazolidinediones
are commonly used as alternatives when metformin therapy fails
[16]. SUs consist of a group of insulin secretagogues, including
glibenclamide, gliclazide and glipizide, which act on K+-channels
on beta cell plasma membrane to enhance insulin secretion
[15,21–24]. As SUs require functioning beta cells to work, their
efficacies may only limit to early stages of type 2 diabetes. Poor
durability and higher secondary failure were reported in previous
studies [25–27]. Common adverse effects documented include
significant weight gain and hypoglycaemia [28,29]. Thiazolidine-
diones, on the other hand, reduce insulin resistance and increase
peripheral glucose uptake through binding to the peroxisome
proliferator-activated receptor-c (PPAR c). They also promote
differentiation of preadipocytes to adipocytes to increase lipogen-
esis [30]. Their durability of glycaemic control is better when
compared with SUs or metformin [31]. AEs including peripheral
oedema caused by fluid retention [32], higher risk of having
congestive heart failure [33] and weight gain markedly limit their
use. Hence they are usually considered only when patients have
significant risks for hypoglycaemia, or are intolerant to the
medications, or when SUs are contraindicated.
Combination therapy with either SUs or thiazolidinediones and
metformin is a common next step if the glycaemic target is not
attained by monotherapy. This results in summation of the
therapeutic effects, offering patients with extra benefits [15–17].
Besides, acarbose is sometimes co-administered with metformin
for obese type 2 diabetic patients. It is an inhibitor of intestinal-
glucosidase located at the intestinal brush border, which helps
reducing the post-prandial blood glucose surge by delaying the
carbohydrate absorption. However, this may lead to diarrhoea,
abdominal pain and bloating.
When combination drug therapy fails to achieve therapeutic
targets, insulin therapy will be initiated to provide sufficient
amount of insulin for maintaining homeostasis of blood glucose
[15,34,35]. Hypoglycaemia is a common and major adverse effect
of insulin [28], which may cause brain damage in severe case.
Despite the development of the above therapies for managing
diabetes, large proportion of diabetic patients did not achieve their
glycaemic targets. In a European cohort of 2,023 type 2 diabetic
patients who were on metformin and either SUs or thiazolidine-
diones, only 25.5% of the patients had adequate glycaemic
control. The average HbA1c level after a mean of 2.6 years of
combination oral antihyperglycaemic agent therapy was 7.2%
[36]. High rates of inadequate glycaemic control were also
observed in China. A cross sectional multicentre study conducted
among 455 type 2 diabetic patients in China reported 45.5% of
the cohort had inadequate glycaemic control with HbA1c$6.5%.
The most common combination therapy used was SUs/glinides
with metformin (25.9%) [37]. Another study also demonstrated
that 75% of 493 diabetic inpatients had inadequate glucose control
[38]. Given the maintenance of good glycaemic control is the key
to prevent diabetic complications, development of safe and
effective approach to manage diabetes is of high priority. Two
novel therapeutic agents, namely incretin mimetics and dipeptidyl
peptidase-4 (DPP-4) inhibitors, have been developed to meet this
ongoing need.
Newer medications for diabetes –Incretin mimetics and
DPP-4 inhibitors
A) Incretin mimetics. Glucagon-like peptide-1 (GLP-1)
analogues or agonists are a group of drugs which mimics
the effect of the endogenous hormone GLP-1. They regulate
blood glucose level by stimulating insulin secretion, sup-
pressing glucagon secretion [39], delaying gastric emptying
and promoting satiety [40]. Unlike some of the OHAs that
lead to weight gain and hypoglycaemia, GLP-1 analogues
have been shown to produce weight loss in type 2 diabetes,
and have a lower risk of causing hypoglycaemia [39–41].
Medications belonging to this drug class include exenatide
and liraglutide.
B) Dipeptidyl peptidase 4-inhibitors (DPP4-I). DPP4-I
are a class of OHAs that regulates blood glucose level by
inhibiting the action of didpeptidyl peptidase 4 (DPP-4).
Under normal physiological condition, incretin hormones
GLP-1 and gastric inhibitory polypeptide (GIP) are released
from the endocrine cells in the small intestine upon food
consumption. They stimulate glucose-dependent release of
insulin [42,43]. However, these incretin hormones are
rapidly degraded by the enzyme DPP-4 [44]. This new drug
class helps prolonging the incretin effects by inhibiting the
action of DPP-4, resulting in enhancement in insulin
secretion, suppression of glucagon secretion and improve-
ment in beta-cell function [45].
DPP4-I are overall very well tolerated and have few side effects
[45]. A potential side effect of DPP4-I is that they may slightly
increase the risk of infection [46]. Also, DPP4-I are slightly less
effective than incretin mimetics on the reduction of HbA1c level in
some patients [45]. They are weight neutral with no effect on
gastric emptying [45]. Nevertheless, DPP4-I have several advan-
tages over incretin mimetics, including oral administration, and
having a lower risk of gastrointestinal discomfort and hypoglycae-
mia [45]. DPP4-I can be administered with or without food, while
drug interactions are rare [45]. Sitagliptin, vildagliptin, saxaglip-
tin, linagliptin and alogliptin are medications belonging to this
drug class.
Novel therapeutic agents and their potential risks
In March 2013, the Food and Drug Administration (FDA)
announced that the type 2 diabetic patients treated with the drug
classes of incretin mimetics and DPP-4 inhibitors may have a
higher risk of pancreatitis and pre-cancerous cellular changes [47].
These findings were supported by a small number of examination
results from the patients who died from unspecified causes [47].
Therefore, there is still no conclusion about their safety risks and
further investigation on the potential pancreatic toxicity associated
with these two new antidiabetic agents is needed.
The Effectiveness of DPP-4 and GLP-1
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Whilst there is no consistent and concrete evidence against the
safety profile of these two new agents, one of the important topics
surrounding these novel agents includes their efficacy in achieving
optimal glycaemic control among diabetic patients on OHAs, in
particular SUs which are used more commonly among patients in
the Asia-Pacific region. We therefore searched the existing
databases to review the effectiveness of the two drug classes as
add-on therapies as compared with SUs or placebo.
Methods
Data sources and searches
A comprehensive search was performed using a combination of
medical subject headings (MeSH) and keywords in international
databases including MEDLINE and EMBASE in August 2013.
Original research studies were searched in the databases from
their inception to August 2013 that reported the effectiveness of
DPP-4 inhibitors and GLP-1 analogues as add-on therapies
among diabetic patients. An additional manual search was
conducted using reference lists from research studies, meta-
analyses and review articles to identify other potential eligible
studies. Table 1 outlined the steps of the search process.
Study selection and quality assessment
We included studies which were designed as randomised
controlled trials conducted in the Asia-Pacific region, including
(1). participants having type 2 diabetes mellitus with inadequate
glycaemic control at enrolment; (2). adults aged $18 years and
were previously treated with SUs as background diabetic regimen;
and that (3). the interventions aimed to assess the drug efficacy of
either DPP-4 inhibitors or GLP-1 analogues as add-on anti-
diabetic therapy. Only studies which were published as complete
full papers in English were included. When the same patient
population was reported in two or more journal articles, only the
most recent and complete study was included.
All potentially relevant publications retrieved by electronic
searching were reviewed independently by two investigators
(HHW and MWK) based on examination of study titles and
abstracts. Those studies which did not meet the inclusion criteria
were excluded. The full-text of the article was obtained if either
reviewer believed that the study might be eligible. Any disagree-
ment was resolved by consensus after discussion or, when
necessary, by appeal to the principal investigator (MCW).
Data extraction and end points
A research nurse (BCF) and a research assistant (STL)
independently extracted relevant information on study partici-
pants, design of interventions and controls, study duration and
outcome measures from each included study by a standardised
extraction form. For this systematic review, the primary outcomes
were clinical values including HbA1c and fasting plasma glucose
(FPG). The secondary outcomes were drug safety tolerability
including the incidence and intensity of AEs, withdrawal due to
accident emergency, symptomatic hypoglycaemic events, homeo-
stasis model assessment for insulin resistance (HOMA-R), HOMA-
beta cell function, etc. The details of all the included studies were
shown in Table 2.
Results
Study characteristics
A total of 522 articles were initially identified to be potentially
relevant in MEDLINE and EMBASE. By reviewing the study
titles and abstracts, 363 articles were excluded. Full-text articles
were retrieved for the remaining 159 articles for formal inclusion
and exclusion. Reasons for exclusion for the majority of trials
included the duplicate publication of the same study, conference
abstracts, and the absence of SUs treated prior to the medication
of DPP-4 inhibitors and GLP-1 analogues. Nine studies fulfilled all
the inclusion criteria and were finally included in this review. The
details of the study selection and the reasons of exclusion were
described in Figure 1.
The effectiveness of GLP-1analogues as add-on therapies
[48–52]
In a double-blind, parallel-group trial by Kaku et al. [48], 264
Japanese patients with type 2 diabetes were randomly given
liraglutide, a GLP-1 analogue, with a dosage of 0.6 mg/day,
0.9 mg/day, or placebo combined with SU monotherapy. The
mean changes in HbA1c from baseline to week 24 for liraglutide
0.6 mg, 0.9 mg and placebo were 21.4660.95%, 21.5660.84%,
Table 1. Search Strategy.
1 (type 2 or type2 or type II or non-insulin dependent or adult onset).tw. (400869)
2 (diabet or antidiabet ).tw. (817946)
3 1 and 2 (199667)
4 Diabetes Mellitus, Type 2/(204183)
5 3 or 4 (262903)
6 (dpp-4 or dpp 4 or dpp4 or dpp-IV or dpp IV or dppIV or dipeptidyl-peptidase 4 or dipeptidyl peptidase 4).tw. (7463)
7 (incretin or glucose-dependent insulinotropic peptide or gastric inhibitory peptide or GIP or glucagon-like peptide-1 or GLP-1).tw. (20226)
8 (sitagliptin or vildagliptin or gliptin or alogliptin or gemigliptin or linagliptin or saxagliptin ).tw. (4061)
9 6 or 7 or 8 (25825)
10 5 and 9 (11338)
11 (asia or pacific or American Samoa or Australia or Brunei or Cambodia or Chin or Hong Kong or Indonesia or Japan or Laos or Macau or Malaysia or
Mongolia or Myanmar or New Zealand or North Korea or Papua New Guinea or Philippine or Singapore or South Korea or Taiwan or Thailand or Timor-
Leste or Vietnam ).tw. (1238790)
12 10 and 11 (522)
doi:10.1371/journal.pone.0090963.t001
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Table 2. Studies included in the present review.
Studies Patients Intervention Control Major Outcomes Ethnicity Findings
1). Kaku
et al, 2010
264 patients on a SUa
(glibenclamide, glicazide
or glimeprimide)
Liraglutide 0.6 mg
daily or 0.9 mg daily
Placebo with no
active ingredients
1). Change of HbA1c at
24 wks
Japanese 21.46% to 21.56%
(liraglutide)vs. 20.40%
(placebo)
2). Proportion reaching
HbA1c,7.0%
46.5% to 71.3%
(liraglutide) vs. 14.8%
(placebo)
2). Seino
et al, 2012b
267 patients aged $20
years with suboptimal
glycaemic control (HbA1c
7.4% to ,10.4%)
Liraglutide 0.6 mg or
0.9 mg daily
Placebo with no
active ingredients
Change of HbA1c at
24 wks
Japanese Mean HbA1c was
reduced by 1.00% to
1.27% points than
placebo.
3). Kadowaki
et al, 2011
179 patients who had
suboptimal glycaemic
control despite use of SUa
alone or in combination
with a biguanide or
thiazolidinedione
Exenatide 5 mg BID
or 10 mg BID offered
subcutaneously
Placebo with no
active ingredients
Change of HbA1c at
24 wks
Japanese 21.34% to 21.62%
(exenatide) vs. 20.28%
(p,0.001)
4). Inagaki
et al, 2012
427 patients aged $20
years with insufficient
glucose control
Exenatide QW 2 mg
daily
Once daily insulin
glarigine (starting
dose 4U)
Change of HbA1c
at 26 wks
Japanese 21.11% (exenatide
QW) vs. 20.68%
(insulin Glargine),
p,0.001 with the 95%
C.I. upper limit
,predefined non-
inferiority margin
(0.4%)
5). Seino
et al, 2012a
311 patients aged
25–81 years with Hba1c
between 7–10% and on
basal insulin +/2 SUa
Lixisenatide starting
from 10 mg to 15 mg
and 20 mg
Placebo with no
active ingredients
Change of HbA1c
at 24 wks
Japan, Re-
public
of Korea,
Taiwan, the
Phillipines
20.77% (lixisenatide)
vs. 0.11% (placebo)
(p,0.0001)
6). Inagaki
et al, 2013
618 patients aged $20
years on SUa or A-GIb
Linagliptin 5 mg
daily
Metformin BD or
TDS, up to 2,250
mg/day
1). Change of HbA1c
at 52 wks
Japanese 1). 20.7% to 20.9%
(linagliptin) vs. 20.8%
to 21.0% (metformin),
p =NSc
2).Hypoglycaemic
attack rates
2). 1.6% to 13.7%
(linagliptin) vs. 3.2% to
15.9% (metformin);
p =NSc
7). Zeng et al,
2013
192 patients on met-
formin and a SUa
Linagliptin 5 mg
daily
Placebo with no
active ingredients
1). Change of HbA1c
at 24 wks
Chinese 1). 20.59% (linagliptin)
vs. 0.08% (placebo),
p,0.0001
2). Change in FPG 2). 23.9 mg/dL
(linagliptin) vs. 15.0%
(placebo), p,0.001
3). Adverse event
rates
3). 38.9% (linagliptin)
vs. 43.8% (placebo),
p =NSc
8). Takihata
et al, 2013
115 patients inadequately
controlled with metformin
and/or sulphonylurea
Sitagliptin 50 mg
daily
Pioglitazone
15 mg daily
Change of HbA1c at
24 wks
Japanese 20.86 (SD 0.63%)
(sitagliptin) vs. 20.58
(SD 0.68%)
(pioglitazone),
p = 0.024
9). Seino
et al, 2012
312 Patients on glime-
piride (1–4 mg/day) with
poor glycaemic control
Alogliptin 12.5
mg or 25 mg
Placebo with no
active ingredients
1). Change of HbA1c at
12 wks
Japanese 1). 20.59% to 20.65%
(alogliptin) vs. 0.35%
(placebo)
2). Adverse events 2). Comparable event
rates with the majority
being mild
aSU= sulphonylurea.
bA-GI = a-glucosidase inhibitors.
cNS = Non-significant.
doi:10.1371/journal.pone.0090963.t002
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and 20.4060.93%, demonstrating its dose-dependent improve-
ment in glycaemic control in type 2 d’iabetic patients. Moreover, a
higher proportion of subjects reached HbA1c ,7.0% with
liraglutide 0.6 mg (46.5%) or 0.9 mg (71.3%) than placebo
(14.8%). In terms of safety, there were minor hypoglycaemic
and gastrointestinal AEs, but no major hypoglycaemic events were
reported.
Similar findings about GLP-1 analogue liraglutide were
reported in one of the trials described in a recent study by Seino
et al. [49]. In this trial, 267 Japanese type 2 diabetic patients were
randomized to one of two daily doses of liraglutide (0.6 or 0.9 mg),
or placebo while continuing SU treatment. Efficacy of the add-on
liraglutide therapy to SU treatment was indicated by the reduction
of the mean HbA1c of 1.00% and 1.27% point in the 0.6 mg and
0.9 mg liraglutide groups when compared to the placebo [49].
Another GLP-1 agonist, exenatide, was studied and analyzed
for its treatment effect and safety in a study involving 179 Japanese
patients with type 2 diabetes. The mean changes in HbA1c from
baseline to week 24 were 21.3460.11%, 21.6260.11%, and
20.2860.15% for exenatide 5 mg, 10 mg, and placebo, respec-
tively (both p,0.001, exenatide vs. placebo) [50]. This suggested
an apparent dose-response relationship in improving glycaemic
control by exenatide. Common adverse effects of exenatide
included hypoglycemia, nausea, and vomiting; however, these
effects diminished over time when patients continued the
treatment.
Another study by Inagaki et al. confirmed the treatment effect
and safety of exenatide with 427 Japanese diabetic patients [51].
Patients were randomly assigned to add exenatide or insulin
glargine to their current treatment. Patients treated with exenatide
achieved a mean change of 21.1160.06% in HbA1c from
baseline to week 26, which was significantly greater than that in
the insulin glargine group (between group difference: 20.43%,
p,0.001). The proportion of subjects who reached HbA1c,7.0%
with exenatide was significantly higher than those with insulin
glargine (42.2% vs. 21.0%, p,0.001). Significantly less patients
treated with exenatide reported symptoms of hypoglycaemia
(9.3% vs. 19.8%, p= 0.002), and nocturnal hypoglycaemic
episodes (0.9% vs. 10.4%, p,0.001) when compared with insulin
glargine group.
A third type of GLP-1 agonist, lixisenatide, was examined in a
randomized, double-blind, placebo-controlled trial by Seino et al.
[52]. This study consisted of 311 patients with type 2 diabetes from
four Asian countries, including Japan, the Republic of Korea,
Taiwan, and the Philippines. These patients were on stable basal
insulin therapy with (70%) or without (30%) SUs at screening.
They were randomized into a lixisenatide or a placebo group for
24 weeks. The mean change in HbA1c from baseline to endpoint
in the lixisenatide group was 20.77%, which was significantly
different from that in the placebo group (between group
difference: 20.88%, p,0.0001). In addition, significantly greater
proportion of patients in this group reached HbA1c ,7.0%
(35.6% vs. 5.2%, p,0.0001). Though gastrointestinal and
Figure 1. Flowchart of study selection.
doi:10.1371/journal.pone.0090963.g001
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hypoglycaemic episodes were more common in the lixisenatide
group when compared with the placebo, none of these events were
severe. A few subjects withdrew due to nausea and vomiting.
The effectiveness of DPP-4 inhibitors as add-on therapies
[53–56]
A well-known DDP-4 inhibitor, linagliptin, has been supported
to be as effective as metformin in providing add-on therapy for
HbA1c reduction. In the 52-week, open-label, multicenter,
parallel-group study conducted by Inagaki et al. [53], long-term
efficacy of once-daily linagliptin 5 mg as add-on therapy to one
oral antidiabetic drug [biguanide, glinide, glitazone, SUs or a-
glucosidase inhibitors (A-GI)] as background therapy was evalu-
ated in 618 Japanese patients with type 2 diabetes mellitus. At
week 52, patients in the linagliptin group with SU background
treatment achieved a significant reduction of 0.7% in mean
HbA1c level, and 31.4% of these patients achieved the therapeutic
target of HbA1c ,7.0%. No significant difference in change in
HbA1c from baseline was observed between linagliptin add-on to
SUs and metformin add-on to SUs. Frequency of reported AEs
was also similar between these two treatment groups among
patients receiving SU background therapy [53].
The efficacy of linagliptin was further supported by a
randomized, placebo-controlled, 24-week trial in China [54].
Once-daily linagliptin 5 mg was administered as add-on therapy
to metformin and SUs in 192 Chinese patients with type 2
diabetes. The placebo-corrected mean change in HbA1c from
baseline was 20.68% (p,0.0001) with linagliptin-based treatment
at week 24. However, concerning the safety and tolerability,
though overall AE rates were similar between the linagliptin and
placebo groups (38.9% vs. 43.8%), drug-related AEs were higher
in linagliptin group than in placebo group (12.5% vs. 2.1%) and
the difference was due to hypoglycaemia (10.4% vs. 0.0%) [54].
The COMPASS study by Takihata et al. [55] also demonstrat-
ed sitagliptin, another DPP-4 inhibitor, was effective in improving
glycaemic control when used as an add-on therapy. This was a
multicenter, open-label, randomized controlled trial among 155
diabetic patients in Japan, comparing the effectiveness of
sitagliptin with pioglitazone as add-on therapy to metformin
and/or SUs. Among patients receiving sitagliptin, the mean
changes in HbA1c level from baseline were 20.6860.46%,
20.9060.60%, and 20.8660.63% at 8, 16 and 24 weeks
respectively. There was a low incidence of AEs including
hypoglycaemia in this treatment group throughout the study
period [55].
Furthermore, Seino et al. [56] showed that add-on therapy of
alogliptin to glimepiride in 312 Japanese diabetic patients achieved
significant reduction in HbA1c. Patients receiving alogliptin once
daily of 12.5 mg and 25 mg as add-on therapy to glimepiride had
significant decrease in HbA1c (20.5960.058% and
20.6560.059% respectively; p,0.0001) when compared with
glimepiride monotherapy (0.3560.059%, p,0.0001). Comparable
number of AEs was reported among the three groups [56]. During
the 40-week open-label extension study, the mean changes from
baseline in HbA1c for the alogliptin 12.5 mg and 25 mg groups
were significant at all time-points, with HbA1c values reduced by
0.42% and 0.58% respectively at the end of the study [56].
Discussion
Nine studies from Asia-Pacific countries, involving a total of
2,685 type 2 diabetic patients, were included in this review.
Duration of the exposure to the drug treatments varied with
studies, ranging from 12 weeks to 52 weeks. Though heterogene-
ities in treatment protocol and drug dosage existed, results showed
that add-on therapy of GLP-1 analogues (liraglutide, exenatide,
and lixisenatide) and DPP-4 inhibitors (linagliptin, sitagliptin, and
aloglitpin) were effective in improving glycaemic control among
type 2 diabetic patients. This conclusion was supported by the
reduction in HbA1c levels at the study endpoint, and the greater
proportion of patients achieved HbA1c targets after the treatment.
These results were consistent with previous Cochrane reviews on
GLP-1 analogues and DPP-4 inhibitors [40,57]. The Cochrane
reviews showed favourable effects of GLP-1 analogues and DPP-4
inhibitors on reduction of HbA1c levels, though most of the
included studies were from Western countries.
The current study focused on diabetic patients from Asia-Pacific
region. This was of particular interest as the risk factors for
diabetes differed between ethnic groups. Existing evidence
suggested that patients from Asia had a high risk of type 2
diabetes when compared to the Western counterparts at the same
BMI. They were more prone to abdominal obesity and low muscle
mass with increased insulin resistance [58]. In addition, racial
differences in response to drug treatment were identified in the
literature. Review by Kim Y. G. [59] reported that when DPP-4
inhibitors were used in oral combination therapy, Asian-dominant
studies showed a greater HbA1c lowering effect than non-Asian-
dominant studies (between group difference: 20.18%, p= 0.006).
All these data highlighted the importance of examining the
efficacy of the two novel drugs as add-on therapies in diabetic
patients from Asia-Pacific countries.
Despite current findings showed improvement in glycaemic
control by this drug class, there was inconclusive information
regarding its long term cardiovascular benefits. SAVOR [60,61],
which was a multicenter, randomized, double-blind, placebo-
controlled, phase 4 trial conducted in 26 countries, reported a
lower HbA1c level in patients receiving saxagliptin when
compared to the placebo group. This study included a total of
16,496 diabetic patients from mainly Western countries (91.7%).
Despite significant improvements in glycaemic control were
observed, this study failed to show any cardioprotective benefit.
Saxagliptin was found to be noninferior to placebo for the
cardiovascular endpoints [61]. Similar results were reported in the
recent EXAMINE trial. This trial recruited patients from different
geographic regions, in which Asia/Pacific region accounted for
around 20% of the total study population. No difference was
observed in the primary end points of cardiovascular death,
myocardial infarction, and stroke between the alogliptin and
placebo groups. In particular, the rates of primary end point
among subjects in Asia/Pacific region were 9.1% and 10.3% in
alogliptin and placebo respectively (95%CI: 0.59–1.30) [62].
To summarize, the findings from these studies supported the
efficacy and acceptable safety profiles of these two newer agents as
add-on therapies to SUs and/or other medications among diabetic
patients not having optimal glycaemic control. Nevertheless, some
of the limitations of these studies should be mentioned. Firstly,
almost all studies were conducted among Japanese patients and
few representations from other ethnic groups were available in
existing literature. This could be explained by the fact that
Japanese type 2 diabetic patients are in general less obese with the
‘thrifty’ genotype, which causes more insulin deficiency and less
insulin resistance than the Western population [63]. In fact, in a
cross-sectional study of 17,000 Japanese type 2 diabetic patients,
72–78% on OHAs were using SUs [64]. Therefore, more research
is needed in order to evaluate the efficacy and safety profile of
incretin mimetics and DPP-4 inhibitors as add-on therapies for
type 2 diabetes in other ethnic groups in the Asia-Pacific region as
different ethnicities might have different pharmacological respons-
The Effectiveness of DPP-4 and GLP-1
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es to these novel agents. For evaluation of their safety profiles,
larger-scale studies are required as the AE rates may be so low -
necessitating more subject enrolment to ensure the studies are
adequately powered.
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